CHA Healthcare Singapore

CHA Healthcare Singapore is a Singapore-incorporated healthcare holding company within the CHA Group that serves as a regional vehicle for Asia-Pacific healthcare investments and clinic operations. The company is part of South Korea's CHA Healthcare/CHA Biotech ecosystem and has been used to build and manage healthcare provider assets in Southeast Asia and Australia. Its most visible activities include becoming the largest shareholder of Singapore Medical Group and participating in a 2024 restructuring in which its controlling stake in Australia's City Fertility was contributed into the former SGX-listed SMG holding structure. The business appears to be focused on commercial healthcare delivery and portfolio management rather than drug R&D, making it more of a healthcare services and strategic holding entity than a biotech developer.